Type 2 diabetes
Conditions
Interventions
dulaglutide
Sponsors
Yokosuka Kyosai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients who are over 20 years old at registration (regardless of gender) (2)Patients diagnosed with type 2 diabetes (3)Patients using liraglutide (0.6mg/0.9mg) (4)Patients who have not been treated with a new diabetes drug for more than 3 months (5)Patients who give their consent to participate in this study
Exclusion criteria
Exclusion criteria: (1) Patients with severe liver damage (up to 3 times normal upper limit of AST and ALT within 28 days before registration) (2) Patients with severe congestive heart failure and acute heart failure (3) Patients taking steroids (4) Patients with a history of diabetic ketoacidosis or diabetic coma during the past 6 months (5) Cancer patients currently undergoing treatment (6) Patients with severe infections, before and after surgery, with severe trauma (7) Patients who are contraindicated or allergic to the test drug (8) Pregnant, possibly pregnant, or wishing to become pregnant during the treatment period and lactating patients (9) Patients who participated in clinical trials or clinical trials of drugs or medical devices at the same time as this study or within 30 days before enrollment in this study (10) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference from baseline in DTSQ 6 months after test start | — |
Secondary
| Measure | Time frame |
|---|---|
| Body weight, blood pressure, pulse rate, liver function (AST, ALT, gamma GTP), renal function (BUN, Cr, eGFR), uric acid, urinary microalbumin, HbA1c, fasting blood glucose, C-peptide level, diabetic retinopathy, etc. Complications Symptoms, adverse events (nausea, vomiting, etc.) | — |
Countries
Japan
Contacts
Public ContactIijima Takahiro
Yokosuka Kyosai Hospital Department of Endocrinology & Metabolism
Outcome results
None listed